Navigation Links
Replidyne to Announce Third Quarter 2007 Earnings
Date:10/9/2007

covery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-Q filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gather analysis and retrieval system (EDGAR) at http://www.sec.gov. All forward-looking statements made in the press release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements in the document.


'/>"/>
SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... ROCKVILLE, Md. , Sept. 16, 2014 /PRNewswire/ ... a biotechnology company developing novel anti-infective biologic and ... infections and diseases, announced today the completion of the ... which highlighted its irritable bowel syndrome ... targeting constipation-predominant IBS (C-IBS). In the ...
(Date:9/16/2014)... 2014  LABSCO, the leading specialty sales agent ... physician office laboratories and alternate healthcare settings is ... it will serve as Siemens Healthcare Diagnostics, exclusive ... as a semi-exclusive sales distributor in specified POL ... United States . LABSCO will be responsible ...
(Date:9/16/2014)... 16, 2014 In preparation for VARTECH 2014, ... cybersecurity company focused on authentication and SSO announced today ... ability to generate a OTP through the presentation of ... of user-based RFID authentication, 2FA,s solutions have leveraged the ... many years. RFID authentication is broadly deployed in healthcare ...
(Date:9/16/2014)... RENU 28, the world's first and only skin gel ... in Australia and New Zealand in mid-August . , The ... tour will make stops in Brisbane on September 16, the ... on the 20th, and Melbourne on the 22nd. , Helping ... to educate people about the new product and business opportunity ...
Breaking Biology Technology:Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 32FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2Global Wellness Company Hosts ASEA Australia Tour September 16-22 2
... , , , ... Bulletin Board: BLFS), a leading developer, manufacturer, and marketer of ... launch of its BloodStor biopreservation media product platform. The ... blood stem cells, as well as other variants for peripheral ...
... , , LAKE MARY, Fla., ... Inc. (NasdaqCM: NGBF) today announced that on August 26, 2009, ... staff indicating that, based on the Company,s stockholders equity as ... the quarter ended June 30, 2009, the Company is no ...
... Mylan Inc. (Nasdaq: MYL ) today is pleased ... notified by the World Health Organization (WHO) Prequalification of Medicines ... for Matrix Unit 8, which is located in the Vizianagaram ... , Mylan Inc., which provides products to customers ...
Cached Biology Technology:BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 2BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 3New Generation Biofuels Receives NASDAQ Notice of Noncompliance with Continued Listing Requirements 2
(Date:9/16/2014)... harks a season of bounty. Fungi of dizzying variety ... woodlands in search of elusive but delectable wild mushrooms. ... the treasure hunt, and their mysterious not-quite-meat, not-quite-vegetable qualities ... mushrooms which you are eating known to science? , ... although some estimates range up to 10 million ...
(Date:9/15/2014)... cell division has evolved a simple, mechanical solution ... the Sept. 11 Science Express. ... counts and misalignments that lead to infertility, miscarriage, ... cell division cause these problems, but what exactly ... Marston of the Wellcome Trust Center for Cell ...
(Date:9/15/2014)... carbon-halogen bonds are produced naturally across all kingdoms of ... with a broad range of biological activities. The presence ... profound influence on their molecular properties. , ... been to find the late-stage, site-specific incorporation of a ... an sp C-H bond (one of the most inert ...
Breaking Biology News(10 mins):What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 3Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3Pitt chemical biologist finds new halogenation enzyme 2
... To be published in the June 1 issue of ... comprehensive profile to date of microRNA (miRNA) expression during ... of which are completely novel) in a developmental and ... time ever in a vertebrate ?a new class of ...
... consortium of researchers has for the first time lifted the ... ?or set of all genes ?of the most destructive enemy ... disease. , Dr. Ralph Dean, professor of plant pathology and ... Research, is the lead author of a research paper that ...
... where you might find love these days. A team ... psychologist found love-related neurophysiological systems inside a magnetic resonance ... brains of 17 young men and women who each ... , The multidisciplinary team found that early, intense romantic ...
Cached Biology News:Researchers uncover sequence of major rice pathogen 2Researchers uncover sequence of major rice pathogen 3Love's all in the brain: fMRI study shows strong, lateralized reward, not sex, drive 2Love's all in the brain: fMRI study shows strong, lateralized reward, not sex, drive 3Love's all in the brain: fMRI study shows strong, lateralized reward, not sex, drive 4Love's all in the brain: fMRI study shows strong, lateralized reward, not sex, drive 5Love's all in the brain: fMRI study shows strong, lateralized reward, not sex, drive 6
... to Ki67 - Proliferation Marker, prediluted ... related nuclear protein, expressed by proliferating cells ... cycle (G1, S, G2 and M phase). ... Ki67 antibodies are useful in establishing the ...
... g of monoclonal antibody reactive against the complex ... are highest in growing cultured cells. SURF1 is ... which is thought to participate in the folding ... this subunit. Mutations of SURF1, particularly ones that ...
Phenytoin-BSA Isolated IgY DFc Drug...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: